Weight regain after successful obesity treatment has plagued patients and physicians for decades, with most individuals recovering lost pounds within years of stopping medication. This challenge could shift dramatically as pharmaceutical companies develop oral alternatives to maintain the benefits of injectable weight-loss drugs without requiring continued injections. The ATTAIN-MAINTAIN trial demonstrates that orforglipron, an oral nonpeptide compound targeting GLP-1 receptors, successfully preserves weight reduction and metabolic improvements initially achieved through injectable GLP-1 therapies. Participants who transitioned from injectable treatments to daily oral orforglipron maintained their weight loss while continuing to experience cardiometabolic benefits including improved glucose control and cardiovascular markers. The oral formulation represents a significant advancement in treatment accessibility, potentially eliminating injection-related barriers that cause some patients to discontinue therapy. This maintenance approach addresses a critical gap in obesity medicine, where the transition period after initial weight loss often determines long-term success. The finding positions orforglipron as a bridge therapy that could extend the durability of weight management interventions. However, the study's timeframe remains limited for assessing truly long-term maintenance, and real-world adherence to daily oral medication may differ from clinical trial conditions. The compound's nonpeptide structure distinguishes it from existing GLP-1 therapies, potentially offering different side effect profiles or drug interactions. This development suggests a future treatment paradigm where patients might begin with injectable therapies for rapid weight reduction, then transition to oral maintenance protocols for sustained benefits without ongoing injections.